The Long-Term Potential of Olaratumab in Soft Tissue Sarcoma

Symantha Melemed, PhD
Published: Monday, May 08, 2017



Symantha Melemed, PhD, global product team lead, Oncology Business Unit, Eli Lilly & Company, discusses the impact of the FDA approval of olaratumab (Lartruvo) and its long-term potential in the field of sarcoma.

The approval of olaratumab is very exciting to treat advanced soft tissue sarcoma as this is an important advance to patients. It is the first FDA approval in first-line treatment for these patients in 40 years, Melemed explains.

Additionally, sarcoma is a very heterogenous disease comprised of more than 50 subtypes. Other ongoing clinical trials are looking at combination regimens of olaratumab and chemotherapy.


Symantha Melemed, PhD, global product team lead, Oncology Business Unit, Eli Lilly & Company, discusses the impact of the FDA approval of olaratumab (Lartruvo) and its long-term potential in the field of sarcoma.

The approval of olaratumab is very exciting to treat advanced soft tissue sarcoma as this is an important advance to patients. It is the first FDA approval in first-line treatment for these patients in 40 years, Melemed explains.

Additionally, sarcoma is a very heterogenous disease comprised of more than 50 subtypes. Other ongoing clinical trials are looking at combination regimens of olaratumab and chemotherapy.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Moving Forward From the Status Quo for the Treatment of Soft Tissue Sarcoma: Key Questions and New Answers to Optimize OutcomesOct 31, 20182.0
Publication Bottom Border
Border Publication
x